359 related articles for article (PubMed ID: 21422921)
1. Complement and glomerular disease: new insights.
Pickering M; Cook HT
Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
[TBL] [Abstract][Full Text] [Related]
2. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
[TBL] [Abstract][Full Text] [Related]
3. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
Sethi S; Fervenza FC
Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
[TBL] [Abstract][Full Text] [Related]
4. Anti-complement therapy for glomerular diseases.
Bomback AS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
[TBL] [Abstract][Full Text] [Related]
5. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
6. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
7. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
8. Complement factor H-related hybrid protein deregulates complement in dense deposit disease.
Chen Q; Wiesener M; Eberhardt HU; Hartmann A; Uzonyi B; Kirschfink M; Amann K; Buettner M; Goodship T; Hugo C; Skerka C; Zipfel PF
J Clin Invest; 2014 Jan; 124(1):145-55. PubMed ID: 24334459
[TBL] [Abstract][Full Text] [Related]
9. Complement factor H related proteins (CFHRs).
Skerka C; Chen Q; Fremeaux-Bacchi V; Roumenina LT
Mol Immunol; 2013 Dec; 56(3):170-80. PubMed ID: 23830046
[TBL] [Abstract][Full Text] [Related]
10. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature.
Manenti L; Gnappi E; Vaglio A; Allegri L; Noris M; Bresin E; Pilato FP; Valoti E; Pasquali S; Buzio C
Nephrol Dial Transplant; 2013 Sep; 28(9):2246-59. PubMed ID: 23787552
[TBL] [Abstract][Full Text] [Related]
11. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
12. Recent insights into C3 glomerulopathy.
Barbour TD; Pickering MC; Cook HT
Nephrol Dial Transplant; 2013 Jul; 28(7):1685-93. PubMed ID: 23479095
[TBL] [Abstract][Full Text] [Related]
13. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
14. Complement and glomerular diseases.
Popat RJ; Robson MG
Nephron Clin Pract; 2014; 128(3-4):238-42. PubMed ID: 25412932
[TBL] [Abstract][Full Text] [Related]
15. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
16. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.
Noris M; Remuzzi G
Am J Kidney Dis; 2015 Aug; 66(2):359-75. PubMed ID: 26032627
[No Abstract] [Full Text] [Related]
17. C3 glomerulopathy - understanding a rare complement-driven renal disease.
Smith RJH; Appel GB; Blom AM; Cook HT; D'Agati VD; Fakhouri F; Fremeaux-Bacchi V; Józsi M; Kavanagh D; Lambris JD; Noris M; Pickering MC; Remuzzi G; de Córdoba SR; Sethi S; Van der Vlag J; Zipfel PF; Nester CM
Nat Rev Nephrol; 2019 Mar; 15(3):129-143. PubMed ID: 30692664
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
Nester CM; Brophy PD
Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
[TBL] [Abstract][Full Text] [Related]
19. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
Xiao X; Pickering MC; Smith RJ
Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
[TBL] [Abstract][Full Text] [Related]
20. Regulating complement in the kidney: insights from CFHR5 nephropathy.
Gale DP; Pickering MC
Dis Model Mech; 2011 Nov; 4(6):721-6. PubMed ID: 22065842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
